Beam Therapeutics ROCE
Mi az Beam Therapeutics ROCE?
A ROCE az Beam Therapeutics Inc. - -13.06%
Mi a ROCE meghatározása?
A befektetett tőke megtérülése (ROCE) olyan pénzügyi arány, amely a vállalat jövedelmezőségét és a tőke felhasználásának hatékonyságát méri.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE a Health Care szektor a NASDAQ-on cégekben a Beam Therapeutics -hoz képest
Mit csinál Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
roce -hoz hasonló cégek Beam Therapeutics
- Mesoblast Ltd nak ROCE -13.19% van
- China Natural Resources Inc nak ROCE -13.15% van
- Cardiovascular Systems nak ROCE -13.14% van
- BondBloxx ETF Trust nak ROCE -13.13% van
- Trip Technologies nak ROCE -13.08% van
- Riskified nak ROCE -13.07% van
- Beam Therapeutics nak ROCE -13.06% van
- Mason Graphite nak ROCE -13.05% van
- Vertex Inc nak ROCE -13.03% van
- Westport Fuel Systems Inc nak ROCE -13.03% van
- WPX Inc nak ROCE -13.03% van
- Spitfyre Capital Inc nak ROCE -13.02% van
- Jump Networks nak ROCE -13.02% van